Actavis’ First Post-Forest Advisory Committee Looks Back At The Past
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest Laboratories’ legacy Bystolic/Diovan combo will be reviewed by FDA’s cardiovascular and renal drugs advisors Sept. 9, but the product isn’t emblematic of the company’s future vision.